Cambridge Investment Research Advisors
SMMT icon

Cambridge Investment Research Advisors’s Summit Therapeutics SMMT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,820
Closed -$656K – 3855
2025
Q2 		$656K Buy
+30,820
New +$703K ﹤0.01% 2294

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Cambridge Investment Research Advisors's SMMT Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 30,820 shares — an estimated $656K sold.

Cambridge Investment Research Advisors first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $656K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Cambridge Investment Research Advisors reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 30,820 Summit Therapeutics shares in Q3 2025, an estimated $656K.
  • Cambridge Investment Research Advisors first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Summit Therapeutics position peaked at $656K in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.